 |
 |
 |
 |
 |
 |
 |
 |
Darunavir (TMC114, Prezista)
Overview
- A Clinical Overview of Darunavir (TMC114, Prezista) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health - Prescribing Information for Darunavir (TMC114, Prezista) (PDF) (February 2008)
From Tibotec Therapeutics - An Interview With Cal Cohen, M.D., a Lead Investigator of the Darunavir (TMC114, Prezista) POWER Trials (June 28, 2006)
Dr. Cohen discusses TMC114's uses, adverse effects and other considerations.
- Prezista Approval (June 23, 2006)
From U.S. Food and Drug Administration
News
- Updates to Prezista (Darunavir) Tablets Labeling (March 11, 2008)
From U.S. Food and Drug Administration - "Dear Healthcare Professional" Letter: New Prescribing Information for Prezista (Darunavir) (March 2008)
Labeling has been updated to include warnings regarding hepatotoxicity.
From Tibotec Therapeutics - New 600-mg Tablet Strength for Darunavir (Prezista) (February 26, 2008)
From U.S. Food and Drug Administration - Tibotec Announces U.S. Expanded Access Program for TMC114 (October 26, 2005)
Though not yet FDA approved, TMC114 is now available for some with multidrug resistance.
From Tibotec Therapeutics - TMC114 Expanded Access Program for People Living With HIV to Begin Enrollment in Autumn of 2005 (June 14, 2005)
From Tibotec Therapeutics
Research
- Clinical Trials Using TMC125 (Regularly Updated)
U.S. and international trials currently recruiting.
From U.S. National Institutes of Health - Literature Citations for TMC125 (Regularly Updated)
From U.S. National Institutes of Health - Clinical Trials Using Darunavir (Regularly Updated)
U.S. and international trials currently recruiting.
From U.S. National Institutes of Health - Efficacy and Safety of Darunavir-Ritonavir Compared With That of Lopinavir-Ritonavir at 48 Weeks in Treatment-Experienced, HIV-Infected Patients in TITAN: A Randomised Controlled Phase III Trial (July 7, 2007)
Study shows greater viral suppression among darunavir patients after 48 weeks.
In The Lancet - Efficacy and Safety of TMC125 (Etravirine) in Treatment-Experienced HIV-1-Infected Patients in DUET-1: 24-Week Results From a Randomised, Double-Blind, Placebo-Controlled Trial (July 7, 2007)
In The Lancet - Efficacy and Safety of TMC125 (Etravirine) in Treatment-Experienced HIV-1-Infected Patients in DUET-2: 24-Week Results From a Randomised, Double-Blind, Placebo-Controlled Trial (July 7, 2007)
In The Lancet - No Patient Left Behind -- Better Treatments for Resistant HIV Infection (July 7, 2007)
A commentary accompanying the publication of the DUET study results comparing etravirine + darunavir/ritonavir to darunavir/ritonavir without etravirine. (Article accessible only to paid subscribers.).
In The Lancet - Adding Etravirine to Darunavir/Ritonavir Improves Virologic Suppression, DUET Studies Show (July 6, 2007)
From aidsmap.com - 48-Week TMC114 + Ritonavir Data Set New Bar for Efficacy in Triple-Class-Experienced Patients (August 15, 2006)
In XVI International AIDS Conference - TMC114 Significantly Outperforms Control Protease Inhibitors in Triple-Class-Experienced Patients, Even in Absence of Enfuvirtide (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment - TMC-114 Sets a New Standard in Salvage Therapy Trials (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Research Updates on Tipranavir, TMC-114 and TMC-125 (December 2004)
A review of the tipranavir RESIST studies, a note on potential tipranavir pricing, and a critical look at two developing rescue drugs.
In TAGline, from Treatment Action Group - Anti-HIV Therapy Update (July 2004)
A quick briefing on tipranavir, TMC-114, capravirine and D-D4FC.
To read PDF, click here
In Project Inform Perspective, from Project Inform - Initial Data on TMC114 in Multiple PI-Experienced Patients (July 16, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - New Anti-HIV Therapies: TMC-125 (March 2002)
To read PDF, click here
From Project Inform
Clinical Management
Clinical Management
  |
  |